Frederick W. Driscoll - 02 Jan 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Director
Issuer ticker: CUE
Reported as of: 02 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2025, 16:00:12 UTC
Prior SEC filing: 18 Jun 2024
Next SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Frederick Driscoll by Colin Sandercock, attorney-in-fact

Key filing fact

Frederick W. Driscoll filed Form 4 for Cue Biopharma, Inc. (CUE) on 03 Jan 2025.

Key facts

This page summarizes Frederick W. Driscoll's Form 4 filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2025, 16:00.

Change

Previous filing in this sequence was filed on 18 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +24,400
Change %
Price: $0.000000
Shares after: 24,400
Date: 02 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,400
Exercise price: $1.09
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

Footnote F2

This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date.